publication date: Dec. 19, 2010

In this issue: 

Phase 0 trials signal FDA’s new reliance on biomarkers for drug development.

NCI faces $32 million budget cut in FY 2006; NIH tells grantees to expect 2.35 percent reduction in award funds.

NCI establishes new Program Project grant guidelines.

Chemotherapy pioneer Howard Skipper dead; his work with leukemia cells in mice led to development of combination therapies.

Download (PDF 2.9MB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.